🗞️ Why in News Following the expiry of Novo Nordisk’s semaglutide patent on March 20, 2026, multiple Indian pharmaceutical companies — Cipla, Sun Pharma, Dr Reddy’s, Biocon, Natco, Zydus, and Mankind Pharma — are preparing to launch generic versions at 50-70% lower prices, even as CDSCO intensifies surveillance against unauthorised GLP-1 sales.
The Editorial Argument
Business Standard argues that while India’s pharma industry is well-positioned to democratise access to semaglutide — one of the most transformative drugs of the decade — the country’s drug oversight system faces serious quality and counterfeiting risks that could undermine both patient safety and India’s global pharma reputation.
The Semaglutide Phenomenon
Semaglutide (brand names: Ozempic for diabetes, Wegovy for weight loss) is a GLP-1 receptor agonist that mimics the incretin hormone, promoting insulin secretion and reducing appetite. It has become the fastest-growing drug category in pharmaceutical history:
| Parameter | Data |
|---|---|
| Global GLP-1 market (2025) | ~$40 billion |
| Novo Nordisk revenue from semaglutide (2025) | ~$30 billion |
| Weight loss efficacy | 15-20% body weight reduction in clinical trials |
| Patent expiry | March 20, 2026 |
| Indian generic price reduction expected | 50-70% |
Indian Companies Ready to Launch
| Company | Preparation Status |
|---|---|
| Cipla | ANDA filed, manufacturing ready |
| Sun Pharma | Clinical trials completed |
| Dr Reddy’s | Biosimilar route |
| Biocon | Biologics expertise leveraged |
| Natco | First-to-file advantage in select markets |
| Zydus | Injectable formulation ready |
| Mankind Pharma | Domestic market focus |
The Quality Challenge
The editorial highlights several risks:
- Counterfeiting: Semaglutide’s high demand and injectable format make it a prime target for counterfeit manufacturers
- Cold chain: GLP-1 agonists require 2-8°C storage; India’s cold chain infrastructure is uneven
- Off-label use: CDSCO has barred weight-loss drug advertisements, but online promotion continues
- Manufacturing complexity: Semaglutide is a peptide — more complex than small-molecule generics, requiring specialised production facilities
- Post-market surveillance: India’s pharmacovigilance system (PvPI) handles only a fraction of adverse drug reactions
CDSCO Regulatory Response
- Barred weight-loss drug advertisements to prevent off-label promotion
- Intensified surveillance and audits against unauthorised GLP-1 sales
- Government monitoring online pharmacies for prescription compliance
- WHO has flagged counterfeit semaglutide as a global concern
India’s Drug Regulatory Architecture
| Body | Role |
|---|---|
| CDSCO | Central regulator — new drug approvals, clinical trials, imports |
| DCGI | Drugs Controller General of India (heads CDSCO) |
| State Drug Controllers | Manufacturing and sales regulation |
| Indian Pharmacopoeia Commission | Drug quality standards |
| PvPI | Pharmacovigilance Programme of India (adverse event monitoring) |
| NLEM | National List of Essential Medicines |
The Bigger Picture — India’s Pharma Opportunity
The semaglutide moment represents a broader pattern: Indian companies excel at manufacturing complex generics at scale, driving down prices globally. The editorial argues this should be paired with regulatory modernisation to maintain credibility:
- India supplies 20% of global generic medicines
- Indian vaccines covered 60% of global immunisation
- But India’s WHO drug prequalification rejections remain a concern
UPSC Relevance
Prelims: GLP-1 receptor agonist, CDSCO, DCGI, Drugs and Cosmetics Act 1940, PvPI, NLEM, patent regime under TRIPS
Mains GS-3: India’s pharmaceutical industry; patent expiry and generic drug access; drug quality regulation
Mains GS-2: Drug regulatory governance; CDSCO capacity; public health policy
📌 Facts Corner — Knowledgepedia
Semaglutide:
- Drug class: GLP-1 receptor agonist
- Brand names: Ozempic (diabetes), Wegovy (weight loss)
- Original manufacturer: Novo Nordisk (Denmark)
- Patent expiry: March 20, 2026
- Weight loss: 15-20% body weight reduction
- Global GLP-1 market: ~$40 billion (2025)
- Indian generic price cut: 50-70%
Indian Companies Launching Generics:
- Cipla, Sun Pharma, Dr Reddy’s, Biocon, Natco, Zydus, Mankind Pharma
Drug Regulation in India:
- CDSCO: Central Drugs Standard Control Organisation
- DCGI: Drugs Controller General of India
- Drugs and Cosmetics Act, 1940
- PvPI: Pharmacovigilance Programme of India
- NLEM: National List of Essential Medicines (updated 2022)
Other Relevant Facts:
- India: “Pharmacy of the World” — 3rd largest by volume
- Generic share: 20% of global supply
- TRIPS Agreement: WTO patent regime (compulsory licensing under Section 84)
- Novartis v. Union of India (2013): Section 3(d) upheld, denying evergreening patents
- WHO prequalification: quality standard for global procurement
Sources: Business Standard, CDSCO